

Funder	Project Title	Funding	Strategic Plan Objective	Institution
Autism Research Institute	Survey on treatment for children with autism with and without seizures	\$7,500	Q4.Other	Children's Learning Institute
National Institutes of Health	Targeted pharmacologic interventions for autism	\$370,481	Q4.L.C	Indiana University-Purdue University Indianapolis
National Institutes of Health	3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD	\$391,103	Q4.L.C	University of California, Los Angeles
National Institutes of Health	4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$564,924	Q4.L.C	Yale University
National Institutes of Health	Pharmacotherapy of pervasive developmental disorders	\$184,587	Q4.L.C	Indiana University-Purdue University Indianapolis
National Institutes of Health	Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study	\$8,775	Q4.S.A	Baylor College of Medicine
Health Resources and Services Administration	Autism Intervention Research Network on Physical Health (AIR-P network)	\$3,651,425	Q4.S.A	Massachusetts General Hospital
Autism Speaks	Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study	\$127,500	Q4.S.A	Baylor College of Medicine
National Institutes of Health	Building a selective inhibitory control tone in autism: An rTMS study	\$222,000	Q4.Other	University of Louisville
National Institutes of Health	The effects of oxytocin on complex social cognition in autism spectrum disorders	\$285,221	Q4.L.A	Mount Sinai School of Medicine
National Institutes of Health	Trial of a glutamate antagonist in the treatment of OCD and autistic disorders	\$770,674	Q4.L.A	National Institutes of Health
National Institutes of Health	3/3-Atomoxetine placebo and parent training in autism	\$277,198	Q4.S.F	University of Rochester
National Institutes of Health	1/3-Atomoxetine placebo and parent training in autism	\$272,700	Q4.S.F	University of Pittsburgh
National Institutes of Health	2/3-Atomoxetine placebo and parent training in autism	\$361,873	Q4.S.F	Ohio State University
National Institutes of Health	ACE Center: The pharmacogenetics of treatment for insistence sameness in autism	\$382,540	Q4.L.A	University of Illinois at Chicago
National Institutes of Health	ACE Center: Understanding repetitive behavior in autism	\$326,665	Q4.L.A	University of California, Los Angeles
National Institutes of Health	ACE Network: Early pharmacotherapy guided by biomarkers in autism	\$1,000,000	Q4.S.F	Wayne State University
National Institutes of Health	Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)	\$619,865	Q4.S.F	Medical University of South Carolina
Department of Defense	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Department of Defense	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School

Funder	Project Title	Funding	Strategic Plan Objective	Institution
Department of Defense	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey
Health Resources and Services Administration	Predictors of effects of propranolol on language & connectivity in autism	\$184,288	Q4.S.F	University of Missouri
National Institutes of Health	1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD	\$366,035	Q4.L.C	Indiana University-Purdue University Indianapolis
Autism Speaks	Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$94,832	Q4.L.A	Stanford University
Autism Speaks	Clinical Trials Network	\$0	Q4.L.A	Autism Speaks (AS)
National Institutes of Health	2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD	\$325,136	Q4.L.C	Seattle Children's Hospital
Autism Speaks	Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine	\$0	Q4.L.A	The Ohio State University
Autism Speaks	Randomized phase 2 trial of RAD001 (an MTOR inhibitor) in patients with tuberous sclerosis complex	\$65,000	Q4.L.A	Childrens Hospital Boston
Autism Speaks	Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$99,974	Q4.L.C	Indiana University
Department of Defense	Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	\$0	Q4.S.C	Holland Bloorview Kids Rehabilitation Hospital

